What is semaglutide?
Semaglutide copies GLP-1, the fullness hormone your gut releases after eating — slowing digestion, quieting appetite, and steadying blood sugar. It's one of the most-studied molecules in modern metabolic medicine.
These articles cover it from every angle: mechanism, dosing, side effects, results measured in trials, and how compounded semaglutide differs from brand-name versions. It's prescription-only through Promise: a licensed provider reviews every request, and not everyone qualifies. If you're starting from zero, begin with the mechanism article — the rest makes more sense once the hormone story is clear.
188 articles on this topic
-

Semaglutide Brand Names: Ozempic, Wegovy, Rybelsus
Ozempic, Wegovy, and Rybelsus all contain semaglutide, but their approved uses and formats differ. Compounded semaglutide is not a brand or generic.
-

How to Get Semaglutide Prescribed
You can get semaglutide through primary care, a specialist clinic, licensed telehealth or a manufacturer-supported route. Every legitimate path requires medical review before a pharmacy dispenses it.
-

Compounded Semaglutide: What It Is in 2026
Compounded semaglutide is a patient-specific prescription, not a generic Ozempic or Wegovy. The ingredient form, dosing label, and post-shortage rules all matter.
-

Semaglutide Pill vs Injection: What Exists
There is a semaglutide pill. There is no tirzepatide pill, and there is unlikely to be one. Understanding why comes down to what happens to a 39-amino-acid peptide in your stomach.
-

Semaglutide Dosage: The 17-Week Ladder
The Wegovy injection schedule for weight management climbs through five doses over sixteen weeks before reaching 2.4 mg. That deliberate pace is the single best-supported way to make the first months tolerable.
-

Semaglutide Side Effects, From Common to Rare
Across pooled STEP-trial safety data, only 4.3% of adults taking semaglutide 2.4 mg stopped treatment because of gastrointestinal side effects.
-

Tirzepatide vs Semaglutide: The Head-to-Head Data
In the SURMOUNT-5 trial, adults with obesity but without diabetes averaged 20.2% body-weight loss on tirzepatide and 13.7% on semaglutide over 72 weeks.
-

Semaglutide Weight Loss Results: 14.9% in 68 Weeks
Adults with obesity in the 68-week STEP 1 trial lost an average of 14.9% of their body weight on weekly semaglutide, while the placebo group averaged 2.4%.
Page 10 of 10 · 188 articles